Search results for "Coronavirus"
New COVID-19 boosters authorized and recommended
The CDC has recommended the new formulations of the mRNA vaccines, targeted at the BA.4 and BA.5 lineages of the omicron variant, for adults and adolescents who last received a COVID-19 shot at least two months ago.
https://acpinternist.org/weekly/archives/2022/09/06/2.htm
6 Sep 2022
Preventive care still on during COVID-19
COVID-19 may foster innovation in primary care as physicians describe various strategies to reconnect with patients, such as leveraging telemedicine visits to also explain the practice's coronavirus-related safety protocols, or systematically reviewing their panels to flag at-risk patients.
https://acpinternist.org/archives/2020/11/preventive-care-still-on-during-covid-19.htm
1 Nov 2020
Frequency of COVID-19 rebound debated in research, ACP/Annals forum
Two letters reported on SARS-CoV-2 viral rebound among patients taking nirmatrelvir-ritonavir. The latest ACP and Annals of Internal Medicine forum brought experts together to discuss this and other clinical challenges in COVID-19 prevention and management on Wednesday, Sept. 7.
https://acpinternist.org/weekly/archives/2022/09/13/2.htm
13 Sep 2022
Latest updates on ACP's priorities, initiatives
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
https://acpinternist.org/archives/2020/03/latest-updates-on-acps-priorities-initiatives.htm
1 Mar 2020
Oral medications for COVID-19 underused among socially vulnerable, CDC study finds
By late May, the rate of prescriptions for molnupiravir and nirmatrelvir/ritonavir was twice as high in the highest-income U.S. ZIP codes as in the lowest, research showed. A CDC webinar on June 28 will discuss efforts to equitably distribute these treatments.
https://acpinternist.org/weekly/archives/2022/06/28/2.htm
28 Jun 2022
Nirmatrelvir/ritonavir rarely leads to rebound, doesn't help average-risk patients, studies find
A retrospective analysis found that symptom rebound occurred in less than 1% of high-risk COVID-19 patients treated with nirmatrelvir/ritonavir, while the manufacturer reported that the drug didn't show significant benefit in average-risk patients.
https://acpinternist.org/weekly/archives/2022/06/21/2.htm
21 Jun 2022
New COVID-19 vaccines tested, authorization changes in progress for existing vaccines
The FDA further limited use of the Johnson & Johnson (Janssen) vaccine and scheduled advisory committee meetings on other vaccine questions. Two non-mRNA vaccines showed effectiveness, and other studies looked at antibody prevalence, home test accuracy, and long-term symptoms.
https://acpinternist.org/weekly/archives/2022/05/10/2.htm
10 May 2022
Celebrate mental health awareness every day
Recognizing mental health entails the individual acknowledging it and seeking help, society not stigmatizing those suffering from mental and behavioral disorders, and the nation providing adequate resources and personnel to address the problem.
https://acpinternist.org/archives/2022/05/celebrate-mental-health-awareness-every-day.htm
1 May 2022
Register now for ACP and Annals of Internal Medicine's COVID-19 Forum IX: Management of Patients with Persistent Symptoms after COVID-19
During the May 24 virtual live event, a panel of experts will discuss challenges related to the care of patients who have lasting symptoms following acute SARS-CoV-2 infection.
https://acpinternist.org/weekly/archives/2022/05/17/3.htm
17 May 2022
Coronavirus outbreak prompts CDC guidance, free ACP resources
The CDC issued advice on dealing with symptomatic patients, ACP is offering an online guide and podcast with free CME, and an Annals of Internal Medicine paper has modeled virus spread in China.
https://acpinternist.org/weekly/archives/2020/02/11/1.htm
11 Feb 2020